Videos

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the efficacy of rucaparib for approved indications based on clinical trial results.

Zachary Nelson, PharmD, BCIDP, BCPS, discussed the past 2 influenza seasons and how they could help predict vaccination and illness rates.

David Zgarrick, PhD, FAPhA, professor in the department of pharmacy and health systems sciences at Northeastern University, also addresses what the future of the pharmacy profession could look like.

Drs Anthony Perissinotti and Kirollos Hanna provide some important considerations for pharmacists in treating chronic lymphocytic leukemia.

Experts discuss the potential future use of CAR T-cell therapy and bispecific therapeutics for chronic lymphocytic leukemia based on data presented at ASH 2021.

Dr Anthony Perissinotti details an effective new therapy on the horizon in chronic lymphocytic leukemia.

Katie Tobon, PharmD, BCOP, and Javier Pinilla-Ibarz, MD, PhD, discuss factors to consider when selecting a BTK inhibitor for CLL therapy, including cytogenetic abnormalities as well as patient- and treatment-related factors.

Bill Ladwig, senior vice president of professional services at Lewis Drug, discussed the pharmacy's 80-year history.

Whitney Hummel, AAS, CPhT-Adv, CSPT, RYT, pharmacy operations coordinator at the Florida Cancer Specialists & Research Institute, discusses burnout for pharmacy technicians.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses the origin of the historical idea that sexual dysfunction in women is primarily based in emotional and/or psychological conditions.

Peter Pitts, a former FDA associate commissioner and president of the Center for Medicine in the Public Interest, discusses the implications of Robert Califf’s appointment to lead the FDA on the future of the agency’s review system.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how rucaparib is currently used when treating patients with ovarian cancer.

Diane McCarthy, director of biologics pipeline development at US Pharmacopeia (USP), discusses USP’s development of mRNA quality guidelines to help companies and regulators bring innovative medicines to market faster.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the mechanism of action of rucaparib in recurrent and second line ovarian cancer, fallopian tube cancer, and peritoneal cancer.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses how hypoactive sexual desire disorder in women was defined and treated historically.

Dr Ryan Jacobs evaluates the use of chemotherapy options for first-line treatment of CLL.

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, share considerations for approaching an individualized treatment regimen for patients with CLL.

Glecaprevir and pibrentasvir (Mavyret) is indicated for the treatment of chronic hepatitis C virus genotype 1-6 infections without cirrhosis or with compensated cirrhosis.

Steven Sims, MD, discussed his upcoming research into how transnasal esophagoscopy could help address disparities in esophageal cancer diagnoses.

Troy Trygstad, PharmD, PhD, MBA, executive director of CPESN USA, discussed how consumers' expectations are changing the future of pharmacy.

Anthony Perissinotti and Kirollos Hanna discuss considerations for selecting treatment regimens in chronic lymphocytic leukemia.

Chronic lymphocytic leukemia experts debate how to prevent or reduce the risk of tumor lysis in patients.

Dr Javier Pinilla-Ibarz leads the discussion on the role of targeted therapy over chemoimmunotherapy as a CLL therapeutic approach and shares NCCN Guidelines recommendations for the use of BTK inhibitors.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some social and cultural aspects that may contribute to hypoactive sexual desire disorder going untreated in women.

Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.

Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

Although marketing may seem intimidating, pharmacy owners should jump in and discover what works best for their pharmacy.

Tyler Woods, PharmD, pharmacy district manager with VMC Buying Group, discussed how partnering together can help independent pharmacies obtain drugs at a lower cost.